Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • FDA provided supportive feedback for a 505(b)(2) NDA pathway for SER-252.
  • Registrational Phase 1b trial to be randomized, double-blind, placebo-controlled.
  • Key milestones: IND Q4 2025, Australia dosing Q4 2025, U.S. enrollment Q1 2026.

Serina Therapeutics (NYSE American: SER) said the U.S. Food and Drug Administration gave constructive feedback that supports advancing SER-252, a POZ-enabled apomorphine formulation aimed at treating advanced Parkinson’s disease, via a 505(b)(2) NDA pathway. The company plans to launch a registrational clinical development program designed to generate data for eventual regulatory submission, beginning with a Phase 1b randomized, double-blind, placebo-controlled study focused on safety, tolerability and pharmacokinetics in patients experiencing motor fluctuations.

The planned SER-252-1b study will enroll patients with advanced Parkinson’s disease and is structured to evaluate multiple cohorts, reflecting an effort to capture dose, safety and PK profiles ahead of larger efficacy trials. Management’s timetable targets a U.S. Investigational New Drug filing in Q4 2025, initial patient dosing in Australia also in Q4 2025, and the start of U.S. patient enrollment in Q1 2026. These milestones outline a clear early-stage clinical path, but they also set expectations for an extended development horizon typical of central nervous system therapeutics.

While the FDA’s feedback reduces some regulatory uncertainty by affirming the 505(b)(2) route as feasible, substantial work remains. The Phase 1b study is an early step that examines tolerability and pharmacokinetic behavior rather than definitive efficacy. Multiple subsequent trial phases will be required to demonstrate clinical benefit and to support a full NDA, which means any commercial or labeling outcomes remain several years away and contingent on positive clinical readouts.

There are additional execution risks tied to the trial design and operational rollout. The multi-cohort structure and international dosing plan increase logistical complexity and could extend timelines if protocol amendments, enrollment shortfalls, or site activation delays occur. Regulatory interactions beyond the current FDA feedback, such as confirmatory discussions on pivotal endpoints or additional data requirements, could also affect timing and costs.